Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. It focuses on developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications. The firm is developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target, truncated O-glycans on MUC16. The company was founded in 1996 and is headquartered in Edmonton, Canada.